Belite Bio Announces Registered Direct Offering of $15 Million

Core Viewpoint - Belite Bio, Inc has announced a securities purchase agreement for the sale of 258,309 American Depositary Shares (ADSs) and warrants, aiming to raise approximately $15 million in gross proceeds, with potential additional proceeds from warrant exercises [1][2]. Group 1: Offering Details - The purchase price for the ADSs and accompanying warrants is set at $58.07 per ADS, equivalent to the current closing price [1]. - The offering is expected to close around February 7, 2025, pending customary closing conditions [1]. - The net proceeds from the offering will be utilized for working capital and general corporate purposes [2]. Group 2: Regulatory Information - The offering is conducted under a shelf registration statement on Form F-3, which was filed with the U.S. Securities and Exchange Commission (SEC) and became effective on January 27, 2025 [3]. - A prospectus supplement will be filed with the SEC and will be available on the SEC's website [3]. Group 3: Company Overview - Belite Bio, Inc is focused on developing novel therapeutics for degenerative retinal diseases with significant unmet medical needs, including Stargardt disease and Geographic Atrophy in advanced dry age-related macular degeneration [5].